These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15140231)

  • 1. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
    Schön MP; Wienrich BG; Drewniok C; Bong AB; Eberle J; Geilen CC; Gollnick H; Schön M
    J Invest Dermatol; 2004 May; 122(5):1266-76. PubMed ID: 15140231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.
    Schön MP; Schön M
    Apoptosis; 2004 May; 9(3):291-8. PubMed ID: 15258460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.
    Schön M; Bong AB; Drewniok C; Herz J; Geilen CC; Reifenberger J; Benninghoff B; Slade HB; Gollnick H; Schön MP
    J Natl Cancer Inst; 2003 Aug; 95(15):1138-49. PubMed ID: 12902443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
    Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
    Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
    Miller AK; Dusing R; Meggison A; Aires D
    J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
    De Giorgi V; Salvini C; Chiarugi A; Paglierani M; Maio V; Nicoletti P; Santucci M; Carli P; Massi D
    Int J Dermatol; 2009 Mar; 48(3):312-21. PubMed ID: 19261026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases.
    Hesling C; D'Incan M; Mansard S; Franck F; Corbin-Duval A; Chèvenet C; Déchelotte P; Madelmont JC; Veyre A; Souteyrand P; Bignon YJ
    Br J Dermatol; 2004 Apr; 150(4):761-7. PubMed ID: 15099376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Topical treatment of melanoma skin metastases with imiquimod].
    Sigüenza M; Pizarro A; Mayor M; Vidaurrázaga C; Miralles L; González-Beato M; Casado M
    Actas Dermosifiliogr; 2005 Mar; 96(2):111-5. PubMed ID: 16476347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
    Ray CM; Kluk M; Grin CM; Grant-Kels JM
    Int J Dermatol; 2005 May; 44(5):428-34. PubMed ID: 15869545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kurbanov BM; Geilen CC; Fecker LF; Orfanos CE; Eberle J
    J Invest Dermatol; 2005 Nov; 125(5):1010-9. PubMed ID: 16297203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells.
    Savarese I; Papi F; D'Errico A; Gori A; Grazzini M; Vannucchi M; Massi D; De Giorgi V
    Clin Exp Dermatol; 2015 Jan; 40(1):27-30. PubMed ID: 25252087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil].
    Florin V; Vercambre-Darras S; Piette F; Mortier L
    Ann Dermatol Venereol; 2008; 135(8-9):603-4. PubMed ID: 18789300
    [No Abstract]   [Full Text] [Related]  

  • 14. New insights into imiquimod's mechanisms of action.
    Martín-García RF
    J Drugs Dermatol; 2004; 3(3):247-9. PubMed ID: 15176157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod 5 percent cream and the treatment of cutaneous malignancy.
    Navi D; Huntley A
    Dermatol Online J; 2004 Jul; 10(1):4. PubMed ID: 15347486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
    Urosevic M; Maier T; Benninghoff B; Slade H; Burg G; Dummer R
    Arch Dermatol; 2003 Oct; 139(10):1325-32. PubMed ID: 14568837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
    He Q; Huang Y; Sheikh MS
    Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins.
    Hussain A; Doucet JP; Gutiérrez M; Ahmad M; Al-Hussein K; Capello D; Gaidano G; Bhatia K
    Haematologica; 2003 Feb; 88(2):167-75. PubMed ID: 12604406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of invasive melanoma with topical imiquimod.
    Moon SD; Spencer JM
    J Drugs Dermatol; 2013 Jan; 12(1):107-8. PubMed ID: 23377337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
    Aspord C; Tramcourt L; Leloup C; Molens JP; Leccia MT; Charles J; Plumas J
    J Invest Dermatol; 2014 Oct; 134(10):2551-2561. PubMed ID: 24751730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.